Factor XI as a target for antithrombotic therapy.

Bane CE, Gailani D
Drug Discov Today. 2014 19 (9): 1454-8

PMID: 24886766 · PMCID: PMC4167190 · DOI:10.1016/j.drudis.2014.05.018

Anticoagulants currently used in clinical practice to treat thromboembolic disorders are effective but increase the risk of severe bleeding because they target proteins that are essential for normal coagulation (hemostasis). Drugs with better safety profiles are required for prevention and treatment of thromboembolic disease. Coagulation factor XIa has emerged as a novel target for safer anticoagulant therapy because of its role in thrombosis and its relatively small contribution to hemostasis.

Copyright © 2014 Elsevier Ltd. All rights reserved.

MeSH Terms (10)

Animals Anticoagulants Blood Coagulation Drug Design Factor XI Factor XIa Fibrinolytic Agents Hemorrhage Humans Thromboembolism

Connections (1)

This publication is referenced by other Labnodes entities: